Bli medlem
Bli medlem

Du är här

2016-05-09

Bavarian Nordic A/S: Bavarian Nordic to Host First Quarter 2016 Results Conference Call

COPENHAGEN, Denmark - May 9, 2016
- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2016 first
quarter results on Friday, May 13, 2016, prior to market open.

The management of Bavarian Nordic will host a conference call at 2:00 pm CET
(8:00 am EDT) on the same day to present the interim results followed by a
Q&A session.

Dial-in numbers for the conference call are: Denmark: +45 32 71 16 60, UK: +44
(0) 20 3427 1912, USA: +1 646 254 3360. Participant code is 6964190.

A live and archived webcast of the call and relevant slides will be available
athttp://bit.ly/1rK1SyK.

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations&Communications.
Phone +45 61 77 47 43

U.S.: Seth Lewis, Vice President, Investor Relations&Communications. Phone: +1
978 341 5271

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies
and vaccines for infectious diseases, based on the Company's live virus
vaccine platform. Through long-standing collaborations, including a
collaboration with the U.S. government, Bavarian Nordic has developed a
portfolio of vaccines for infectious diseases, including the non-replicating
smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the
United States and other governments. The vaccine is approved in the European
Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its
partner Janssen are developing an Ebola vaccine regimen, which has been
fast-tracked, with the backing of worldwide health authorities, and a vaccine
for the prevention and treatment of HPV. Additionally, in collaboration with
the National Cancer Institute, Bavarian Nordic has developed a portfolio of
active cancer immunotherapies, including PROSTVAC®, which is currently in
Phase 3 clinical development for the treatment of advanced prostate cancer.
The company has partnered with Bristol-Myers Squibb for the potential
commercialization of PROSTVAC. For more information
visitwww.bavarian-nordic.comor follow us on Twitter@bavariannordic.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire

HUG#2010688

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.